专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005061710A1 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF BCL-2 审中-公开
标题翻译：用于调节BCL-2的低分子化合物
公开(公告)号：WO2005061710A1
公开(公告)日：2005-07-07
申请号：PCT/DK2004/000917
申请日：2004-12-23
申请人： SANTARIS PHARMA A/S , FRIEDEN, Miriam , HANSEN, Jens, Bo , ØRUM, Henrik , WESTERGAARD, Majken , THRUE, Charlotte, Albæck
发明人： FRIEDEN, Miriam , HANSEN, Jens, Bo , ØRUM, Henrik , WESTERGAARD, Majken , THRUE, Charlotte, Albæck
IPC分类号： C12N15/11
CPC分类号： C12N15/1135 , A61K48/00 , C07H21/00 , C12N2310/315 , C12N2310/3231
摘要： The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position N°1459 (5’) to N°1476 (3’) of the human Bcl-2 mRNA, said target binding domain having the formula: 5’-[DNA/RNA) 0-1 -(LNA/LNA*) 2-7 -(DNA/RNA/LNA*) 4-14 -(LNA/LNA*) 2-7 -(DNA/RNA) 0-1 ]-3’ and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (-O-P(O,S)-O). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.
摘要翻译：本发明提供了改进的低聚化合物，特别是寡核苷酸化合物，以及调节人类Bcl-2基因表达的方法。特别地，本发明涉及长度为10-30个核碱基的寡聚化合物，其包含可与从第1459（5'）到第1476（3'）的碱基位置特异性杂交的靶结合结构域所述靶结合结构域具有下式：5' - [DNA / RNA] 0-1-（LNA / LNA *）2-7-（DNA / RNA / LNA *）4-14-（LNA / LNA *）2-7-（DNA / RNA）0-1] -3'，并且所述靶结合结构域包含由硫代磷酸酯基团连接的至少两个LNA核苷酸或LNA类似物核苷酸（-OP（O，S）-O ）。特别地，寡核苷酸主要或完全硫醇化。本发明还提供了这种寡聚物或缀合物或嵌合体用于治疗与Bcl-2基因（例如癌症）的表达相关的各种疾病的用途。

2. 发明申请

WO2004046160A8 AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN 审中-公开
标题翻译：氨基-LNA，THIO-LNA和ALPHA-L-OXY-LN
公开(公告)号：WO2004046160A8
公开(公告)日：2005-07-07
申请号：PCT/DK0300788
申请日：2003-11-18
申请人： SANTARIS PHARMA AS , CHRISTENSEN SIGNE M , MIKKELSEN NIKOLAJ DAM , FRIEDEN MIRIAM , HANSEN HENRIK FRYDENLUND , KOCH TROELS , PEDERSEN DANIEL SEJER , ROSENBOHM CHRISTOPH , THRUE CHARLOTTE ALBAEK , WESTERGAARD MAJKEN
发明人： CHRISTENSEN SIGNE M , MIKKELSEN NIKOLAJ DAM , FRIEDEN MIRIAM , HANSEN HENRIK FRYDENLUND , KOCH TROELS , PEDERSEN DANIEL SEJER , ROSENBOHM CHRISTOPH , THRUE CHARLOTTE ALBAEK , WESTERGAARD MAJKEN
IPC分类号： A61K31/7088 , C07H21/00 , C12N15/11
CPC分类号： C12N15/113 , A61K31/7088 , C07H19/04 , C07H19/06 , C07H19/16 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/111 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/3231 , C12N2310/341 , C12N2310/344 , C12N2320/30 , C12N2320/51
摘要： A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
摘要翻译：一种新型的药物，其包含可用于反义治疗的锁定核酸（LNA）。这些新型寡核苷酸具有改善的反义性质。所述新型寡核苷酸由至少一种选自β-D-硫基/氨基-LNA或α-L-氧基/硫代/氨基-LNA的LNA组成。包含LNA的寡核苷酸还可以包括DNA和/或RNA核苷酸。

3. 发明申请

WO2004046160A3 AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN 审中-公开
公开(公告)号：WO2004046160A3
公开(公告)日：2004-06-03
申请号：PCT/DK2003/000788
申请日：2003-11-18
申请人： SANTARIS PHARMA A/S , CHRISTENSEN, Signe, M. , MIKKELSEN, Nikolaj, Dam , FRIEDEN, Miriam , HANSEN, Henrik, Frydenlund , KOCH, Troels , PEDERSEN, Daniel, Sejer , ROSENBOHM, Chritoph , THRUE, Charlotte, Albæk , WESTERGAARD, Majken
发明人： CHRISTENSEN, Signe, M. , MIKKELSEN, Nikolaj, Dam , FRIEDEN, Miriam , HANSEN, Henrik, Frydenlund , KOCH, Troels , PEDERSEN, Daniel, Sejer , ROSENBOHM, Chritoph , THRUE, Charlotte, Albæk , WESTERGAARD, Majken
IPC分类号： A61K31/7088
摘要： A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

4. 发明申请

WO2004046160A2 ANTISENSE DESIGN 审中-公开
标题翻译：防伪设计
公开(公告)号：WO2004046160A2
公开(公告)日：2004-06-03
申请号：PCT/DK0300788
申请日：2003-11-18
申请人： SANTARIS PHARMA AS , CHRISTENSEN SIGNE M , MIKKELSEN NIKOLAJ DAM , FRIEDEN MIRIAM , HANSEN HENRIK FRYDENLUND , KOCH TROELS , PEDERSEN DANIEL SEJER , ROSENBOHM CHRISTOPH , THRUE CHARLOTTE ALBAEK , WESTERGAARD MAJKEN
发明人： CHRISTENSEN SIGNE M , MIKKELSEN NIKOLAJ DAM , FRIEDEN MIRIAM , HANSEN HENRIK FRYDENLUND , KOCH TROELS , PEDERSEN DANIEL SEJER , ROSENBOHM CHRISTOPH , THRUE CHARLOTTE ALBAEK , WESTERGAARD MAJKEN
IPC分类号： A61K31/7088 , C07H21/00 , C12N15/11
CPC分类号： C12N15/113 , A61K31/7088 , C07H19/04 , C07H19/06 , C07H19/16 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/111 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/3231 , C12N2310/341 , C12N2310/344 , C12N2320/30 , C12N2320/51
摘要： A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
摘要翻译：一种新型的药物，其包含可用于反义治疗的锁定核酸（LNA）。这些新型寡核苷酸具有改善的反义性质。所述新型寡核苷酸由至少一种选自β-D-硫基/氨基-LNA或α-L-氧基/硫代/氨基-LNA的LNA组成。包含LNA的寡核苷酸还可以包括DNA和/或RNA核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式